Donate
Lifespan.io > Institutions > Alerity Therapeutics
×

Menu

Back

Alerity Therapeutics

https://alteritytherapeutics.com/
Email: [email protected]

Organization Description

Part of the Life Biosciences group of companies, Alterity is developing first-in-class therapies to treat neurodegenerative disease. Their lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.

Team

David Sinclair, Ph.D.

David Sinclair, Ph.D.

Harvard Medical School - Professor of Genetics
Stay Connected
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
Privacy Policy
Terms Of Use
Sitemap

The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of Lifespan Research Institute/Lifespan.io, its directors, officers or employees.

Powered by MMD